A comparison of cilostazol and pentoxifylline for treating intermittent claudication
A comparison of cilostazol and pentoxifylline for treating intermittent claudication
复制标题
DOI：
10.1016/s0002-9343(00)00569-6
复制
发表时间：
2000-11-01
影响因子：
5.9
通讯作者：
Strandness, DE
中科院分区：
文献类型：
--
作者：
Dawson, DL;Cutler, BS;Strandness, DE
目的：我们进行了一项随机、双盲、安慰剂对照、多中心试验，以评估西洛他唑和己酮茶碱的相对疗效和安全性。患者和方法：我们从54个血管门诊诊所招募了中度至重度跛行患者，包括美国空军、退伍军人事务部、三级保健和大学医疗中心。在922名同意的患者中，698名符合纳入标准，随机分配到西洛他唑（100mg口服，每天两次）、己酮茶碱（400mg口服，每天3次）或安慰剂的盲法治疗组。在基线和4、8、12、16、20和24周时，我们通过等速、可变等级的跑步机测试来测量最大步行距离。结果：与接受己酮茶碱（n = 232）或安慰剂（n = 239）的患者相比，西洛他唑治疗的患者（n = 227）在每次基线后随访时的平均最大步行距离显著增加。治疗24周后，西洛他唑组平均最大步行距离平均增加107米（比基线平均增加54%），显著高于己酮茶碱组64米的改善（平均增加30%）
PURPOSE: We performed a randomized, double-blind, placebo-controlled, multicenter trial to evaluate the relative efficacy and safety of cilostazol and pentoxifylline.PATIENTS AND METHODS: We enrolled patients with moderate-to-severe claudication from 54 outpatient vascular clinics, including sites at Air Force, Veterans Affairs, tertiary care, and university medical centers in the United States. Of 922 consenting patients, 698 met the inclusion criteria and were randomly assigned to blinded treatment with either cilostazol (100 mg orally twice a day), pentoxifylline (400 mg orally 3 times a day), or placebo. We measured maximal walking distance with constant-speed, variable-grade treadmill testing at baseline and at 4, 8, 12, 16, 20, and 24 weeks.RESULTS: Mean maximal walking distance of cilostazol-treated patients (n = 227) was significantly greater at every postbaseline visit compared with patients who received pentoxifylline (n = 232) or placebo (n = 239). After 24 weeks of treatment, mean maximal walking distance increased by a mean of 107 m (a mean percent increase of 54% from baseline) in the cilostazol group, significantly more than the 64-m improvement (a 30% mean percent increase) with pentoxifylline (P